KBR Inc. (KBR) came out with quarterly earnings of $0.99 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.91 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.43%. A quarter ago, it was expected that this the engineering, construction company would post earnings of $0.95 per share when it actually produced earnings of $1.02, delivering a surprise of +7.37%.Over the last four ...

Primo Brands (PRMB) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.37%. A quarter ago, it was expected that this maker of pure-play water solutions would post earnings of $0.38 per share when it actually produced earnings of $0.41, delivering a surprise of +7.89%.Over the last fo ...

Core Viewpoint - Universal Health Services reported quarterly earnings of $5.88 per share, missing the Zacks Consensus Estimate of $5.92 per share, but showing an increase from $4.92 per share a year ago, indicating a year-over-year growth in earnings despite the miss [1] Group 1: Earnings Performance - The company experienced an earnings surprise of -0.63% for the recent quarter, while it had a positive surprise of +22.1% in the previous quarter [1][2] - Over the last four quarters, Universal Health Services has surpassed consensus EPS estimates three times [2] Group 2: Revenue Performance - The company posted revenues of $4.49 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.05%, and showing an increase from $4.11 billion year-over-year [2] - Universal Health Services has topped consensus revenue estimates three times over the last four quarters [2] Group 3: Stock Performance and Outlook - Shares of Universal Health Services have increased by approximately 5.5% since the beginning of the year, outperforming the S&P 500, which gained 0.7% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] Group 4: Earnings Estimates and Industry Outlook - The current consensus EPS estimate for the upcoming quarter is $5.27 on revenues of $4.32 billion, and for the current fiscal year, it is $23.52 on revenues of $18.26 billion [7] - The Medical - Hospital industry is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Core Viewpoint - Veracyte reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company achieved earnings of $0.53 per share, surpassing the Zacks Consensus Estimate of $0.41 per share, and up from $0.36 per share a year ago, representing an earnings surprise of +30.06% [1]. - Revenues for the quarter reached $140.64 million, exceeding the Zacks Consensus Estimate by 1.41% and up from $118.63 million in the same quarter last year [2]. Market Performance - Veracyte shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 0.7% [3]. - The company's stock is currently rated Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.34, with projected revenues of $131.36 million, and for the current fiscal year, the EPS estimate is $1.61 on revenues of $577.29 million [7]. - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8].

分组1 - Amerisafe reported quarterly earnings of $0.51 per share, missing the Zacks Consensus Estimate of $0.57 per share, and down from $0.67 per share a year ago, representing an earnings surprise of -10.53% [1] - The company posted revenues of $80.75 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.55%, compared to year-ago revenues of $73.51 million [2] - Over the last four quarters, Amerisafe has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] 分组2 - The stock has lost about 3% since the beginning of the year, while the S&P 500 has gained 0.7% [3] - The current consensus EPS estimate for the coming quarter is $0.54 on revenues of $80.14 million, and for the current fiscal year, it is $2.13 on revenues of $330.12 million [7] - The Zacks Industry Rank for Insurance - Accident and Health is currently in the top 27% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, but down from $0.17 per share a year ago, indicating a mixed performance in earnings despite a positive surprise [1][2]. Financial Performance - The company achieved revenues of $283.99 million for the quarter ended December 2025, which fell short of the Zacks Consensus Estimate by 2.94%, compared to $259.6 million in the same quarter last year [2]. - Over the last four quarters, Acadia has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2]. Stock Performance - Acadia shares have declined approximately 7.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $268.17 million, and for the current fiscal year, it is $0.68 on revenues of $1.19 billion [7]. - The trend of earnings estimate revisions for Acadia was mixed prior to the earnings release, which may influence future stock movements [6]. Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8].

分组1 - Chord Energy Corporation reported quarterly earnings of $1.28 per share, exceeding the Zacks Consensus Estimate of $1.17 per share, but down from $3.49 per share a year ago, representing an earnings surprise of +9.03% [1] - The company posted revenues of $876.6 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 3.75%, and down from $1.45 billion year-over-year [2] - Chord Energy Corporation shares have increased by approximately 13.2% since the beginning of the year, outperforming the S&P 500's gain of 0.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $876.07 million, and for the current fiscal year, it is $4.27 on revenues of $3.6 billion [7] - The Zacks Industry Rank for Oil and Gas - Exploration and Production - United States is currently in the bottom 15% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Chord Energy Corporation was unfavorable ahead of the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, suggesting expected underperformance in the near future [6]

分组1 - Salesforce reported quarterly earnings of $3.81 per share, exceeding the Zacks Consensus Estimate of $3.03 per share, and up from $2.78 per share a year ago, representing an earnings surprise of +25.69% [1] - The company achieved revenues of $11.2 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 0.32%, and an increase from $9.99 billion year-over-year [2] - Over the last four quarters, Salesforce has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 30% since the beginning of the year, while the S&P 500 has gained 0.7% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of $2.96 on $10.95 billion in revenues for the coming quarter and $12.99 on $45.94 billion in revenues for the current fiscal year [7] - The Zacks Industry Rank places the Internet - Software sector in the top 38% of over 250 Zacks industries, indicating a favorable environment for stock performance [8]

分组1 - Enovix Corporation reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of +18.84% [1] - The company posted revenues of $11.27 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 11.05%, and showing an increase from $9.72 million year-over-year [2] - Enovix Corporation has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year, while the S&P 500 has gained 0.7% [3] - The current consensus EPS estimate for the coming quarter is -$0.18 on revenues of $7.39 million, and for the current fiscal year, it is -$0.71 on revenues of $61.85 million [7] - The Zacks Industry Rank for Electronics - Miscellaneous Products is in the top 16% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

BJ's Restaurants (BJRI) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.00%. A quarter ago, it was expected that this restaurant chain would post a loss of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of +500%.Over the last four quarters, the c ...